Brief: Anpac Bio Announces Positive Results From Multi-Year Lung Cancer Prognosis And Recurrence Clinical Study
04/09/2020 12:49
Sept 4 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO ANNOUNCES POSITIVE RESULTS FROM A MULTI-YEAR
LUNG
CANCER PROGNOSIS AND RECURRENCE CLINICAL STUDY
* ANPAC BIO- INITIAL RESULTS FROM STUDY INDICATE CDA
TECHNOLOGY
COULD ACT AS A VIABLE TOOL FOR MEASURING AND EVALUATING
RECURRENCE FOLLOWING REMISSION
* ANPAC BIO - INITIAL RESULTS FROM STUDY INDICATE CDA
TECHNOLOGY
COULD ACT AS VIABLE TOOL FOR MEASURING, EVALUATING LUNG CANCER
TREATMENT, EFFICACY
Source text for Eikon: ID:nGNXbbGC4X
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022